DOCSLIB.ORG

SARS-Cov-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SARS-Cov-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know? PERSPECTIVES www.jasn.org SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know? Madeleine R. Heldman and Ajit P. Limaye Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, Washington JASN 32: ccc–ccc, 2021. doi: https://doi.org/10.1681/ASN.2021010023 Coronavirus disease 2019 (COVID-19) will far outweigh risks of vaccination. viral vector–based vaccines could be- has had a major effect on kidney and Accordingly, current guidance from come replication competent and cause other solid organ transplant recipients.1 multiple professional organizations disease, especially in immunocompro- In addition to public health measures, recommend vaccination for all eligible mised individuals. For example, in cells improved access to testing, and thera- organ transplant recipients.2,4,5 concurrently infected with two different peutic developments, vaccination has Each vaccine platform has distinct AdVes, homologous recombination of emerged as a key tool for controlling safety considerations for kidney transplant genetic elements could occur and result the ongoing pandemic. In December recipients. Live (replication-competent) in the emergence of new, pathogenic, 2020, multiple regulatory agencies vaccines are generally contraindicated in replication-competent AdV types.9 This worldwide authorized the use of two immunocompromised individuals be- has been observed in patients with ad- mRNAvaccines for severe acute respiratory cause of a risk of vaccine-acquired dis- vanced HIV disease during natural AdV syndrome coronavirus 2 (SARS-CoV- ease.6 The SARS-CoV-2 candidate vaccines infections, and is theoretically possible 2), and several other vaccine platforms that are furthest along in development with AdV vector–based vaccines in pa- are in advanced-stage clinical trials.2,3 do not contain replication-competent tients who are immunocompromised Individuals who have received a trans- SARS-CoV-2 virus, and therefore do with a concurrent wild-type AdV infec- planted kidney or other solid organ not carry risk of SARS-CoV-2 infection tion.9 Although infrequent, severe AdV have been identified as high-risk popu- (Table 1). infections, including allograft nephritis, lations and prioritized for vaccination However, viral vector–based vaccines can occur in kidney transplant recipients in public health guidelines, but unfortu- that incorporate viruses other than during natural infection.9 Notably, nately have been excluded from major SARS-CoV-2 are in advanced-phase vaccine-associated AdV disease has not SARS-CoV-2 vaccine clinical trials.1,2 studies, including adenovirus (AdV) been reported, albeit there is little ex- Thus, studies are urgently needed to vector–based vaccines that have been li- perience in immunocompromised characterize the safety, immunogenicity, censed in Europe. These vaccines consist populations. and ultimately, efficacy of SARS-CoV-2 of intact virions that are engineered to It should be emphasized that, de- vaccines for such patients. include the gene encoding the SARS- spite the theoretical concerns with Below, we provide an overview of CoV-2 spike protein, a technique that replication-deficient viral vector–based SARS-CoV-2 vaccines and highlight leverages the viral vector’s ability to effi- vaccines, immunosuppression is not key concepts that should be considered ciently infect cells and enhances spike considered a contraindication to their in evaluating their safety in solid organ gene delivery. Vaccines that use viral vec- use.11 Replication-competent viral- transplant recipients. Despite the theo- tors contain either replication-deficient vectored vaccines carry a greater risk of retical concerns described below, we em- or replication-competent viruses (Ta- vaccine-derived vector infection in phasize that available evidence from ble 1). The majority of viral-vectored studies demonstrates safety and effi- vaccines in the most advanced phases cacy in the general population. Because of development have been rendered Published online ahead of print. Publication date of the known substantial risks of replication-deficient through deletion available at www.jasn.org. COVID-19–associated morbidity and of genes essential for replication.8 By Correspondence: Dr.AjitP.Limaye,Professorof mortality in recipients of kidney and limiting vector replication, the potential Medicine, Division of Allergy and Infectious Dis- eases, University of Washington, 1959 NE Pacific other solid organs, and the long track for vaccine-associated AdV disease is Street, Seattle, WA 98195-6174. Email: limaye@uw. record of safety of other vaccinations in greatly diminished. edu such recipients, we anticipate the ben- There are, however, theoretical mech- Copyright © 2021 by the American Society of efits of selected SARS-CoV-2 vaccines anisms by which replication-deficient Nephrology JASN 32: ccc–ccc, 2021 ISSN : 1046-6673/3205-ccc 1 2 PERSPECTIVES Table 1. Major SARS-CoV-2 platforms in developmenta Vaccine Name Safety and Efficacy in the General Specific Considerations for JASN Vaccine Platform Vehicle Phase of Development Adjuvant (Manufacturer) Population Kidney Transplant Recipients mRNA BNTb162b2 (Pfizer/ mRNA encapsulated in Authorized for Unadjuvanted, 95% efficacy in phase 3 trials.1 Does not contain live virus. No BioNTech) lipid nanoparticles emergency use in the but lipid Anaphylaxis has been evidence of vaccine- mRNA-1273 (Moderna) United States and other nanoparticles reported. Avoid in patients induced off-target immune www.jasn.org countries possess with a known allergy to a responses in large phase 3 natural vaccine component (e.g., clinical trials.2,3 adjuvant polyethylene glycol). Close activity7 monitoring after administration for patients with a history of anaphylaxis to any food or drug.3 Replication-defective AZD122 (Oxford/ Human-chimpanzee Phase 3 Unadjuvanted 70%–90% efficacy depending Removal of genes necessary viral vectors AstraZeneca) adenovirus (ChAdOx1) on dose in phase 3 trials.8 for replication reduces risk of Transverse myelitis vaccine-associated AdV reported.8 disease.9 Theoretical risk of JNJ78436735/ Human adenovirus Phase 3 Unadjuvanted Unknown emergence of new AdV type Ad26.COV2.S (Janssen) (Ad26) with replicative potential Convidecia (Ad5-nCov) Human adenovirus (Ad5) Approved for limited use Unadjuvanted Unknown through homologous in China recombination, although Sputnik V (Gamaleya) Human adenovirus (Ad5 Early use in Russia, Unadjuvanted Unknown this has never been and Ad26 in Belarus, and Argentina demonstrated to occur with consecutive doses) AdV-vectored vaccines.9 Protein subunit NVX-CoV2373 (Novavax) Recombinant spike Phase 3 Matrix-M1 Unknown Does not contain live virus. glycoprotein system plus Matrix-M1 contains the an additional, same QS21 saponin as the unnamed AS01B adjuvant system adjuvant contained in the recombinant varicella zoster vaccine.7 SARS-CoV-2 recombinant Recombinant spike Phase 2 AS03 adjuvant Unknown High incidence of anti-HLA protein formulation protein antibodies in KTR (GSK/Sanofi) vaccinated with AS03- adjuvanted influenza vaccines, but no association between AS03 exposure and 3,10 JASN rejection. EpiVacCorona (Vector Peptide epitope Early use in Russia Unknown Limited data available 32: Institute) ccc Whole-inactivated BBIBP-CoV (Sinopharm) Whole-inactivated SARS- Limited use in China and Unknown Unknown Does not contain live virus. – ccc (killed) CoronaVac (SinoVac) CoV-2 viral particles other countries Limited data available in peer-reviewed literature. ,2021 GSK, GlaskoSmithKline; KTR, kidney transplant recipients. aDoes not include all candidate vaccines or platforms under investigation; limited to platforms in advanced stages of clinical development or authorized for use as of December 31, 2020. www.jasn.org PERSPECTIVES patients who are immunocompromised allograft rejection. Concern about adju- organ transplant recipients suggest they and should only be administered under vant safety in organ transplant recipients have relative humoral response rates that carefully controlled circumstances (spe- arose from observations of an unusually are approximately 50%–70%ofthose cifically, clinical trials). Other vaccine high incidence of anti-HLA antibodies seen in nontransplant populations.6,7 candidates that are in advanced stages in kidney transplant recipients who re- Patients with ESRD may have more a ro- of development, including mRNA, pro- ceived the 2009 influenza A(H1Na1) bust response to vaccines before rather tein subunit, or whole virus–inactivated pdm09 vaccine, which contained the than after kidney transplant,6 and when SARS-CoV-2 vaccines, do not contain squalene-based AS03 adjuvant system.6,7 possible, SARS-CoV-2 vaccines should intact virus and thus do not carry a risk However, only a fraction of these anti- be given before transplantation.2 In the of vaccine-associated infection.3 HLA antibodies were donor specific, and post-transplant setting, age .65 years, Induction of generalized systemic in- a subsequent investigation of .10,000 more recent transplantation, use of flammation by either the vaccine antigen solid organ transplant recipients found mycophenolate and mammalian target or an associated adjuvant, or by more no definitive association between the of rapamycin inhibitors, and lower specific cellular and humoral cross- AS03 adjuvant system and acute allograft graft function are associated with de- reactivity between vaccine epitopes rejection.6 The AS01B adjuvant used in creased serologic
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • COVID-19 Vaccination Programme: Information for Healthcare Practitioners
    COVID-19 vaccination programme Information for healthcare practitioners Republished 6 August 2021 Version 3.10 1 COVID-19 vaccination programme: Information for healthcare practitioners Document information This document was originally published provisionally, ahead of authorisation of any COVID-19 vaccine in the UK, to provide information to those involved in the COVID-19 national vaccination programme before it began in December 2020. Following authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines and Healthcare products Regulatory Agency being given to the COVID-19 Vaccine Pfizer BioNTech on 2 December 2020, the COVID-19 Vaccine AstraZeneca on 30 December 2020 and the COVID-19 Vaccine Moderna on 8 January 2021, this document has been updated to provide specific information about the storage and preparation of these vaccines. Information about any other COVID-19 vaccines which are given regulatory approval will be added when this occurs. The information in this document was correct at time of publication. As COVID-19 is an evolving disease, much is still being learned about both the disease and the vaccines which have been developed to prevent it. For this reason, some information may change. Updates will be made to this document as new information becomes available. Please use the online version to ensure you are accessing the latest version. 2 COVID-19 vaccination programme: Information for healthcare practitioners Document revision information Version Details Date number 1.0 Document created 27 November 2020 2.0 Vaccine specific information about the COVID-19 mRNA 4 Vaccine BNT162b2 (Pfizer BioNTech) added December 2020 2.1 1.
    [Show full text]
  • Considerations for Causality Assessment of Neurological And
    Occasional essay J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp-2021-326924 on 6 August 2021. Downloaded from Considerations for causality assessment of neurological and neuropsychiatric complications of SARS- CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder Matt Butler ,1 Arina Tamborska,2,3 Greta K Wood,2,3 Mark Ellul,4 Rhys H Thomas,5,6 Ian Galea ,7 Sarah Pett,8 Bhagteshwar Singh,3 Tom Solomon,4 Thomas Arthur Pollak,9 Benedict D Michael,2,3 Timothy R Nicholson10 For numbered affiliations see INTRODUCTION More severe potential adverse effects in the open- end of article. The scientific community rapidly responded to label phase of vaccine roll- outs are being collected the COVID-19 pandemic by developing novel through national surveillance systems. In the USA, Correspondence to SARS- CoV-2 vaccines (table 1). As of early June Dr Timothy R Nicholson, King’s roughly 372 adverse events have been reported per College London, London WC2R 2021, an estimated 2 billion doses have been million doses, which is a lower rate than expected 1 2LS, UK; timothy. nicholson@ administered worldwide. Neurological adverse based on the clinical trials.6 kcl. ac. uk events following immunisation (AEFI), such as In the UK, adverse events are reported via the cerebral venous sinus thrombosis and demyelin- MB and AT are joint first Coronavirus Yellow Card reporting website. As of ating episodes, have been reported. In some coun- authors. early June 2021, approximately 250 000 Yellow tries, these have led to the temporary halting of BDM and TRN are joint senior Cards have been submitted, equating to around authors.
    [Show full text]
  • The Impact of Social Media on the Individuals and Society During Covid-19-Lockdown Situation
    Indian J. Soc. & Pol. 07 (02) : 51-54 : 2020 ISSN: 2348-0084 ( PRINT ) 31 July 2020 ISSN: 2455-2127(ONLINE) THE IMPACT OF SOCIAL MEDIA ON THE INDIVIDUALS AND SOCIETY DURING COVID-19-LOCKDOWN SITUATION (An analytical study of the social media impact on individuals & society during the COVID pandemic) JOHN STEVENSON PATRA1 1M.B.A., M.A., PGDUPDL, Ex. Faculty, VRS & YRN College, Chirala, A.P. INDIA ABSTRACT Social Media can be defined as those forms of electronic communication (such as websites for social networking and micro-blogging) through which users create online communities to share information, ideas, personal messages, and other content (such as videos). As per wiki, Social media are interactive computer-mediated technologies that facilitate the creation or sharing of information, ideas, career interests and other forms of expression via virtual communities and networks. Some of the most popular Social Media include – Facebook, Tiktok (presently banned in India), We Chat, Instagram, Twitter, Linkedin, etc.,. Other famous platforms like Whatsapp, Telegram, Snap chat, Youtube, Zoom, Google meet, etc., are also off late deemed as part of Social Media. Users usually access social media services via web-based apps on desktops and laptops, or download services that offer social media functionality to their mobile devices (e.g., smartphones and tablets). Through Social Media, individuals, communities, and organizations share, co-create, discuss, participate and modify user-generated content or self-curated content posted online. This study paper deals with the role played by the Social Media in India in the situations prevailing on account of the COVID-19 pandemic and Lockdowns KEYWORDS: Pandemic, COVID-19, Lockdown, Social Networking COVID-19 AND LOCKDOWN 19 pandemic.
    [Show full text]
  • Virality Project Weekly Briefing #18 April 20, 2021 - April 27, 2021
    Virality Project Weekly Briefing #18 April 20, 2021 - April 27, 2021 This report was created by analysts from the Virality Project, a coalition of research entities focused on real-time detection, analysis, and response to COVID-19 anti-vaccine mis- and disinformation. The Virality Project aims to support information exchange between public health officials, government, and social media platforms through weekly briefings and real-time incident response. Public officials and health organizations interested in officially joining this collaboration can reach the partnership at [email protected]. In this briefing: Events This Week ● Vaccine “shedding” narrative about menstrual cycles creates confusion about COVID-19 vaccines’ impact on women’s health among anti-vaccine and wellness communities. ● Israeli study with small sample size finds correlation between Pfizer vaccine and shingles. Online users twist the findings to suggest a link between vaccines and herpes. ● CDC reports 5,800 “breakthrough” cases of people getting coronavirus after vaccination. Some accounts have seized on this data to suggest that vaccines are ineffective. ● An unfounded claim that a 12-year-old was hospitalized due to a vaccine trial spread among anti-vaccine groups resulting in safety concerns about vaccinating children. ● Anti-vaccine accounts attempt to hijack #RollUpYourSleeves after NBC TV Special to draw attention to vaccine misinformation. Non-English Language ● Chinese language video from Guo Wengui spreads false narrative and Foreign Spotlight that no COVID-19 vaccines work. ● Children’s Health Defense article translated into Chinese spreads on WeChat. ● Report from Israeli People’s Committee uses unverified reports to claim Pfizer vaccine more dangerous than others Ongoing Themes and ● New film featuring footage from the “Worldwide Rally for Tactics Freedom” marketed widely online among anti-vaccine and health freedom groups.
    [Show full text]
  • WHO COVID-19 Database Search Strategy (Updated 26 May 2021)
    Search purpose: Systematic search of the COVID-19 literature performed Monday through Friday for the WHO Database. Search strategy as of 26 May 2021. Searches performed by Tomas Allen, Kavita Kothari, and Martha Knuth. Use following commands to pull daily new entries: Entry_date:( [20210101 TO 20210120]) Entry_date:( 20210105) Duplicates: Duplicates are found in EndNote and Distillr using the Wichor method. Further screening is done by expert reviewers but some duplicates may still be in the database. Daily Search Strategy: Database Daily Search Strategy Medline (coronavir* OR corona virus* OR corona pandemic* OR betacoronavir* OR covid19 OR covid OR (Ovid) nCoV OR novel CoV OR CoV 2 OR CoV2 OR sarscov2 OR sars2 OR 2019nCoV OR wuhan virus* OR 1946- NCOV19 OR solidarity trial OR operation warp speed OR COVAX OR "ACT-Accelerator" OR BNT162b2 OR comirnaty OR "mRNA-1273" OR CoviShield OR AZD1222 OR Sputnik V OR CoronaVac OR "BBIBP-CorV" OR "Ad26.CoV2.S" OR "JNJ-78436735" OR Ad26COVS1 OR VAC31518 OR EpiVacCorona OR Convidicea OR "Ad5-nCoV" OR Covaxin OR CoviVac OR ZF2001 OR "NVX-CoV2373" OR "ZyCoV-D" OR CIGB 66 OR CVnCoV OR "INO-4800" OR "VIR-7831" OR "UB-612" OR BNT162 OR Soberana 1 OR Soberana 2 OR "B.1.1.7" OR "VOC 202012/01" OR "VOC202012/01" OR "VUI 202012/01" OR "VUI202012/01" OR "501Y.V1" OR UK Variant OR Kent Variant OR "VOC 202102/02" OR "VOC202102/02" OR "B.1.351" OR "VOC 202012/02" OR "VOC202012/02" OR "20H/501.V2" OR "20H/501Y.V2" OR "501Y.V2" OR "501.V2" OR South African Variant OR "B.1.1.28.1" OR "B.1.1.28" OR "B.1.1.248" OR
    [Show full text]
  • 1 Title: Interim Report of a Phase 2 Randomized Trial of a Plant
    medRxiv preprint doi: https://doi.org/10.1101/2021.05.14.21257248; this version posted May 17, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Title: Interim Report of a Phase 2 Randomized Trial of a Plant-Produced Virus-Like Particle 2 Vaccine for Covid-19 in Healthy Adults Aged 18-64 and Older Adults Aged 65 and Older 3 Authors: Philipe Gobeil1, Stéphane Pillet1, Annie Séguin1, Iohann Boulay1, Asif Mahmood1, 4 Donald C Vinh 2, Nathalie Charland1, Philippe Boutet3, François Roman3, Robbert Van Der 5 Most4, Maria de los Angeles Ceregido Perez3, Brian J Ward1,2†, Nathalie Landry1† 6 Affiliations: 1 Medicago Inc., 1020 route de l’Église office 600, Québec, QC, Canada, G1V 7 3V9; 2 Research Institute of the McGill University Health Centre, 1001 Decarie St, Montreal, 8 QC H4A 3J1; 3 GlaxoSmithKline Biologicals SA (Vaccines), Avenue Fleming 20, 1300 Wavre, 9 Belgium; 4 GlaxoSmithKline Biologicals SA (Vaccines), rue de l’Institut 89, 1330 Rixensart, 10 Belgium; † These individuals are equally credited as senior authors. 11 * Corresponding author: Nathalie Landry, 1020 Route de l’Église, Bureau 600, Québec, Qc, 12 Canada, G1V 3V9; Tel. 418 658 9393; Fax. 418 658 6699; [email protected] 13 Abstract 14 The rapid spread of SARS-CoV-2 globally continues to impact humanity on a global scale with 15 rising morbidity and mortality. Despite the development of multiple effective vaccines, new 16 vaccines continue to be required to supply ongoing demand.
    [Show full text]
  • Immunogenicity and Safety of a Third Dose, and Immune Persistence Of
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.23.21261026; this version posted July 25, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. 1 Immunogenicity and safety of a third dose, and immune persistence of 2 CoronaVac vaccine in healthy adults aged 18-59 years: interim results 3 from a double-blind, randomized, placebo-controlled phase 2 clinical 4 trial 5 6 Hongxing Pan MSc1*, Qianhui Wu MPH2*, Gang Zeng Ph.D.3*, Juan Yang Ph.D.1, Deyu 7 Jiang MSc4, Xiaowei Deng MSc2, Kai Chu MSc1, Wen Zheng BSc2, Fengcai Zhu M.D.5†, 8 Hongjie Yu M.D. Ph.D.2,6,7†, Weidong Yin MBA8† 9 10 Affiliations 11 1. Vaccine Evaluation Institute, Jiangsu Provincial Center for Disease Control and 12 Prevention, Nanjing, China 13 2. School of Public Health, Fudan University, Key Laboratory of Public Health Safety, 14 Ministry of Education, Shanghai, China 15 3. Clinical Research Department, Sinovac Biotech Co., Ltd., Beijing, China 16 4. Covid-19 Vaccine Department, Sinovac Life Sciences Co., Ltd., Beijing, China 17 5. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China 18 6. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, 19 Shanghai, China 20 7. Department of Infectious Diseases, Huashan Hospital, Fudan University, 21 Shanghai, China 22 8. Sinovac Biotech Co., Ltd., Beijing, China NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
    [Show full text]
  • Testimony of Nadera Lopez-Garrity Oppose S.C.R. No. 10 Health, Human Services and Medicaid Committee February 26, 2020
    Testimony of Nadera Lopez-Garrity Oppose S.C.R. No. 10 Health, Human Services and Medicaid Committee February 26, 2020 Chairman Burke, Vice Chair Huffman, Ranking Minority Member Antonio and honorable members of the Health, Human Services and Medicaid Committee. Thank you for the opportunity to speak today in opposition of Senate Concurrent Resolution 10. My name is Nadera Lopez-Garrity and I am the mother of a child whose overall wellbeing compels me to be here today. I oppose S.C.R. No. 10 due to concerning proposed rule changes in the Ohio Administrative Code (OAC) 3701-36-05. I particularly oppose the financial incentives to penalize county health departments whose citizens decline a pharmaceutical product and the intention of publicly posting the rates of consuming such biologics, which not only has no bearing on true immunity but such disclosure would be in violation of Ohioans constitutional rights. The proposed OAC 3701-36-05 rules outlined in paragraph B, section 10, seeks to increase the vaccination rates of children entering kindergarten, seventh and twelfth grades in accordance to section 331.671 of the Revised Code via financial incentives. Financially penalizing county health departments unless they meet such standards will not only lead to coercive tactics that are highly unethical and in violation of the Nuremberg code but fails to address the shortcomings of a practice that is not bullet-proof in neither preventing disease nor promoting good health, both of which the ODH has been entrusted to protect and improve, as they proudly assert in their mission statement. The scientifically sound realities of primary, secondary and tertiary vaccine failure must be taken into consideration if we are to concern ourselves with the prevention of disease, promotion of good health outcomes and the assurance of “safe and healthy environments.” We recently witnessed this reality last fall when there was an outbreak of Bordetella pertussis (whooping cough) in Warren County Ohio.
    [Show full text]
  • An Overview of COVID Vaccine Clinical Trial Results & Some Challenges
    An overview of COVID vaccine clinical trial results & some challenges DCVMN Webinar December 8th, 2020 Access to COVID-19 tools ACCESSACCESS TO TOCOVID-19 COVID-19 TOOLS TOOLS (ACT) (ACT) ACCELERATOR ACCELERATOR (ACT) accelerator A GlobalA GlobalCollaboration Collaboration to Accelerate tothe AccelerateDevelopment, the Production Development, and Equitable Production Access to New and Equitable AccessCOVID-19 to New diagnostics, COVID-19 therapeutics diagnostics, and vaccines therapeutics and vaccines VACCINES DIAGNOSTICS THERAPEUTICS (COVAX) Development & Manufacturing Led by CEPI, with industry Procurement and delivery at scale Led by Gavi Policy and allocation Led by WHO Key players SOURCE: (ACT) ACCELERATOR Commitment and Call to Action 24th April 2020 ACT-A / COVAX governance COVAX COORDINATION MEETING CEPI Board Co-Chair: Jane Halton Co-Chair: Dr. Ngozi Gavi Board Workstream leads + DCVMN and IFPMA-selected Reps As needed – R&D&M Chair; COVAX IPG Chair Development & Manufacturing Procurement and delivery Policy and allocation (COVAX) at scale Led by (with industry) Led by Led by R&D&M Investment Committee COVAX Independent Product Group Technical Review Group Portfolio Group Vaccine Teams SWAT teams RAG 3 COVAX SWAT teams are being set up as a joint platform to accelerate COVID- 19 Vaccine development and manufacturing by addressing common challenges together Timely and targeted Multilateral Knowledge-based Resource-efficient Addresses specific cross- Establishes a dialogue Identifies and collates Coordinates between developer technical and global joint effort most relevant materials different organizations/ challenges as they are across different COVID-19 and insights across the initiatives to limit raised and/or identified vaccines organizations broader COVID-19 duplications and ensure on an ongoing basis (incl.
    [Show full text]
  • Download This Issue
    COVID ECONOMICS VETTED AND REAL-TIME PAPERS ECONOMIC EPIDEMIOLOGY: ISSUE 48 A REVIEW 10 SEPTEMBER 2020 David McAdams INDIVIDUALISM Bo Bian, Jingjing Li, Ting Xu FORECASTING THE SHOCK and Natasha Z. Foutz Felipe Meza ENTREPRENEUR DEBT AVERSION IS WHO TRUSTED? Mikael Paaso, Vesa Pursiainen Nirosha Elsem Varghese, Iryna and Sami Torstila Sabat, Sebastian Neuman‑Böhme, SUPPLY CHAIN DISRUPTION Jonas Schreyögg, Tom Stargardt, Matthias Meier and Eugenio Pinto Aleksandra Torbica, Job van Exel, PANDEMICS, POVERTY, AND Pedro Pita Barros and Werner Brouwer SOCIAL COHESION ECONOMISTS: FROM VILLAINS Remi Jedwab, Amjad M. Khan, Richard TO HEROES? Damania, Jason Russ and Esha D. Zaver Diane Coyle Covid Economics Vetted and Real-Time Papers Covid Economics, Vetted and Real-Time Papers, from CEPR, brings together formal investigations on the economic issues emanating from the Covid outbreak, based on explicit theory and/or empirical evidence, to improve the knowledge base. Founder: Beatrice Weder di Mauro, President of CEPR Editor: Charles Wyplosz, Graduate Institute Geneva and CEPR Contact: Submissions should be made at https://portal.cepr.org/call-papers- covid-economics. Other queries should be sent to [email protected]. Copyright for the papers appearing in this issue of Covid Economics: Vetted and Real-Time Papers is held by the individual authors. The Centre for Economic Policy Research (CEPR) The Centre for Economic Policy Research (CEPR) is a network of over 1,500 research economists based mostly in European universities. The Centre’s goal is twofold: to promote world-class research, and to get the policy-relevant results into the hands of key decision-makers. CEPR’s guiding principle is ‘Research excellence with policy relevance’.
    [Show full text]
  • Periodic Update on AEFI
    CONSOLIDATED REGIONAL AND GLOBAL INFORMATION ON ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) AGAINST COVID-19 AND OTHER UPDATES Thirteenth report WASHINGTON, DC Updated: 10 May 2021 1 OFFICIAL REPORTS ON PHARMACOVIGILANCE PROGRAMS CANADA • As of 30 April 2021, 13,420,198 doses of the COVID-19 vaccines of Pfizer-BioNTech, Moderna, Oxford- AstraZeneca, and the vaccine Covishield (AstraZeneca manufactured by the Serum Institute of India), had been administered. • A total of 4,548 individual reports of one or more adverse events (0.034% of doses administered) were received. Of these, 748 were considered serious events (0.006% of doses administered), with anaphylaxis being the one most frequently reported. • Of total reports, there were 2,072 non-serious and 520 serious events associated with the Pfizer-BioNTech vaccine. For the Moderna vaccine, 1,457 non-serious and 103 serious events were reported; for Covishield, there were 201 non-serious and 48 serious events, and for Oxford-AstraZeneca, 65 non-serious events and 62 serious events. • A total of 13,596 adverse events following immunization (AEFI) were reported, with 4,548 reports with one or more events. The most frequently reported non-serious adverse events were injection-site reactions, paresthesia, itching, hives, headache, hypoesthesia, and nausea. There were 61 reports of anaphylaxis. • Although 55% of vaccine doses were administered to women as of 30 April, and 45% to men, most of the reported adverse events were in women (84.3% of total doses). At the same time, 43.0% of total events were reported for people between the ages of 18 and 49, who account for 24% of people vaccinated.
    [Show full text]